Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.

The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase 4 inhibitor or (b) a phosphodiesterase 4 inhibitor and a second active pharmaceutical ingredient.

Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

The invention provides a die suitable for producing a multi-chamber softgel capsule. The die comprises a die pocket defined by a die pocket wall and a bottom surface. The die comprises one or more partitioning walls dividing the die pocket into two or more chambers The top of the land of the partitioning walls have a lowest point that is lower than the plane formed by the top of the land along the perimeter of the die pocket wall by a gap. A die roll comprising a plurality of the dies is also provided, as well as rotary-die encapsulation machine comprising the die roll.

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

The present disclosure relates to a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, and provides a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, including a water phase part containing water, and an oil phase part dispersed in the water phase part and made of nanoparticle containing a perfluorocarbon compound, wherein the oil phase part contains oxygen gas, and the oxygen gas is released in sustained release. According to the present disclosure, there are advantages of preventing hair loss or promoting hair growth by increasing the amount of oxygen gas supplied to the hair bulb and the oxygen release time from the hair bulb.

Disclosed are methods of delivering a therapeutic to a target site of a subject comprising administering a lipid capsule to a target site of a subject, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject, wherein the alternating electric field releases the therapeutic from lipid capsule at the target site of the subject. Disclosed are methods of increasing target site specific release of a therapeutic agent in a subject comprising administering a lipid capsule to a target site of a subject, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site of the subject, thereby increasing the target site specific release of the therapeutic agent. Disclosed are methods of treating comprise administering a lipid capsule to a target site of a subject in need thereof, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject in need thereof, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site of the subject in need thereof. Disclosed are methods of killing a cell comprising administering a lipid capsule to a target site, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field for a period of time, to the target site, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site, wherein the target site comprises a cell, wherein the therapeutic kills the cell.

Disclosed herein is a chewable article for oral mucosa delivery of a composition. The chewable system comprises a chewable base with the composition embedded, coated, integrated or dispersed therein. The composition may be pressurized, oxygenated, and/or atomized. The composition may be released as an aerosol. In one embodiment, the chewable system comprises a pressurized capsule that dissolves or ruptures in the mouth to release a burst of the composition. The chewable system may be configured to allow the composition facing to the buccal mucosa.